查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1994510

2026年全球心血管基因检测市场报告

Cardiovascular Genetic Testing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，心血管基因检测市场规模迅速扩张。预计该市场将从2025年的39.3亿美元成长到2026年的43.5亿美元，复合年增长率（CAGR）为10.8%。过去几年成长要素包括：人们对遗传性心血管疾病的认识不断提高、分子诊断技术的进步、基因定序成本的下降、遗传咨询服务的普及以及心血管基因组学研究的活性化。

预计未来几年心血管基因检测市场将快速成长，到2030年将达到66.2亿美元，复合年增长率（CAGR）为11.0%。预测期内的成长预计将受到以下因素的推动：对精准医疗方法的需求不断增长、基于人群的基因筛检日益普及、人工智慧驱动的突变分析不断扩展、基因组学在临床决策中的应用不断深入，以及人们对心血管疾病预防保健的日益重视。预测期内的关键趋势包括：预测性基因风险评估的普及、多基因panel检测的广泛应用、生物资讯学和人工智慧分析的融合发展、药物药物基因体学学检测应用的扩展，以及人们对个人化心血管保健的日益关注。

预计未来几年，心血管疾病盛行率的上升将推动心血管基因检测市场的成长。心血管疾病（CVD）涵盖多种影响心臟和血管的疾病，例如心肌梗塞、中风和高血压。导致心血管疾病盛行率上升的一个主要因素是与都市化相关的久坐生活方式，这种生活方式会导致肥胖、高血压和代谢性疾病。心血管疾病发生率的上升正在推动心血管基因检测的需求。早期识别遗传风险有助于制定个人化的预防策略和标靶治疗，从而降低严重心臟併发症的风险。例如，根据总部位于美国的非营利组织美国心臟协会的数据，截至2024年1月，心血管疾病的年龄调整死亡率预计将上升至2024年的每10万人233.3人，比2023年的每10万人224.4人增加4.0%。因此，心血管疾病盛行率的上升正在推动心血管基因检测市场的成长。

心血管基因检测市场的主要企业正致力于开发创新解决方案，例如医生主导的检测，以确保医疗必要性，并根据患者的个别情况进行个人化检测，从而减少不必要的检测及其相关成本。医师主导的检测是指医疗专业人员为指南病患健康评估、监测或管理而要求进行的诊断程序。例如，2025年9月，总部位于美国的非营利综合学术医疗保健系统麻省总医院布莱根医疗中心与博德临床实验室和麻省总医院布莱根分子医学实验室合作，推出了一项基因检测，用于评估八种心血管疾病的遗传风险。这项由临床医生主导的检测以自费形式提供，可评估患者对心房颤动、冠状动脉疾病、第2型糖尿病、高胆固醇症胆固醇血症、高血压、胸主动脉瘤和静脉血栓栓塞症等疾病的遗传易感性。此检测方法的开发利用了美国国立卫生研究院 (NIH) 「我们所有人」(All of Us) 研究计画中 236,393 名参与者的基因型和临床数据。研究人员使用 PRSmix（一种弹性网路建模技术，可将多个成分评分合併为针对每种疾病的单一综合风险评分）整合了公开的多基因风险评分。高解析度遗传数据由博德临床实验室 (Broad Clinical Labs) 透过混合基因组-EXOME检测获得，结果由获得 CLIA 认证的麻省总医院布莱根分子医学实验室 (Mass General Brigham Laboratory for Molecular Medicine) 进行分析，并以易于理解的报告形式呈现给患者。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球心血管基因检测市场：吸引力评分与分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 工业4.0和智慧製造
    • 金融科技、区块链、监管科技、数位金融
  • 主要趋势
    • 扩大预测性遗传风险评估的应用
    • 多基因检测的扩展
    • 生物资讯学与人工智慧分析的融合正在不断发展。
    • 拓展药物基因体学检测的应用范围
    • 人们越来越关注个人化心血管护理

第五章 终端用户产业市场分析

  • 医院和诊所
  • 诊断检测实验室
  • 研究机构
  • 遗传咨询中心
  • 製药公司

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球心血管基因检测市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 全球心血管基因检测市场规模、对比及成长率分析
  • 全球心血管基因检测市场表现：规模与成长，2020-2025年
  • 全球心血管基因检测市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按测试类型
  • 预测性测试、基因带原检测、产前和新生儿测试、诊断性测试、药物基因测试和其他类型的测试。
  • 疾病特异性
  • 遗传性心肌病、肥厚型心肌病（HCM）、扩大性心肌病（DCM）、心律不整、主动脉疾病及其他疾病
  • 透过技术
  • 细胞遗传学检测、生化检测、分子检测
  • 透过使用
  • 染色体分析、遗传疾病诊断、心血管疾病诊断及其他应用。
  • 最终用户
  • 医院和诊所、诊断检测实验室、研究机构、遗传咨询中心、製药公司和直接消费者检测。
  • 按类型细分：预测测试
  • 无症状风险评估、遗传性突变筛检、多基因风险评估、晚发性疾病预测、易感基因检测。
  • 按类型细分：基因带原检测
  • 常染色体隐性携带者筛检、连锁携带者筛检、扩展携带者筛检方案、单基因携带者筛检、基于家族病史的基因带原检测
  • 按类型细分：产前和新生儿筛检
  • 非侵入性产前基因检测、侵入性产前诊断检测、新生儿代谢筛检、先天性心臟疾病基因筛检、新生儿基因组检测
  • 按类型细分：诊断测试
  • 单基因诊断检测、多基因检测、全EXOME显子组诊断检测、全基因组诊断检测、突变确认检测
  • 按类型细分：药物基因体学组学检测
  • 药物反应基因检测、药物不良反应风险检测、剂量优化基因检测、抗凝血反应检测、心血管药物代谢检测。
  • 按类型细分：其他测试类型
  • 级联家族检测、基于人群的基因筛检、调查性基因检测、确诊和追踪检测、临床试验基因检测

第十章 区域与国别分析

  • 全球心血管基因检测市场：按地区划分，实际结果与预测，2020-2025年、2025-2030年预测、2035年预测
  • 全球心血管基因检测市场：依国家划分，实际结果与预测，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 心血管基因检测市场：竞争格局及市场占有率（2024年）
  • 心血管基因检测市场：公司估值矩阵
  • 心血管基因检测市场：公司概况
    • Labcorp Holdings Inc.
    • Quest Diagnostics Inc.
    • ICON plc
    • Illumina Inc.
    • Apollo Hospitals

第37章 其他大型企业和创新企业

  • OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., Health in Code SL

第38章：全球市场竞争基准分析与仪錶板

第39章：预计进入市场的Start-Ups

第四十章 重大併购

第41章 具有高市场潜力的国家、细分市场与策略

  • 2030年心血管基因检测市场：提供新机会的国家
  • 2030年心血管基因检测市场：新兴细分市场机会
  • 2030年心血管基因检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第42章附录

简介目录
Product Code: HS5MCGTE01_G26Q1

Cardiovascular genetic testing involves examining an individual's DNA to detect inherited genetic variants that elevate the likelihood of developing diseases of the heart and blood vessels, supporting early identification, individualized treatment decisions, and focused preventive measures. It allows healthcare professionals to estimate disease risk, inform medication choices, evaluate hereditary predisposition, and facilitate proactive cardiovascular care through precision-based medical strategies.

The primary testing types of cardiovascular genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and other testing categories. Predictive testing consists of genetic assessments that evaluate an individual's likelihood of developing cardiovascular disorders prior to symptom onset. These tests are applied to diseases such as inherited cardiomyopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmias, aortopathies, and other related conditions. The technologies involved include cytogenetic testing, biochemical testing, and molecular testing. The applications cover chromosome analysis, genetic disease identification, cardiovascular disease diagnosis, and other uses, while the end users include hospitals and clinics, diagnostic laboratories, research organizations, genetic counseling centers, pharmaceutical companies, and direct-to-consumer testing providers.

Tariffs are impacting the cardiovascular genetic testing market by increasing costs of imported sequencing instruments, reagents, bioinformatics hardware, and advanced laboratory equipment. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for test kit manufacturing and distribution. These tariffs are increasing testing expenses and slowing laboratory expansion. However, they are also encouraging domestic reagent production, localized sequencing infrastructure, and regional bioinformatics platform development that strengthen long-term testing capacity.

The cardiovascular genetic testing market research report is one of a series of new reports from The Business Research Company that provides cardiovascular genetic testing market statistics, including cardiovascular genetic testing industry global market size, regional shares, competitors with a cardiovascular genetic testing market share, detailed cardiovascular genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular genetic testing industry. This cardiovascular genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiovascular genetic testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing awareness of inherited cardiovascular disorders, expansion of molecular diagnostic capabilities, declining costs of genetic sequencing, growing use of genetic counseling services, increased research in cardiovascular genomics.

The cardiovascular genetic testing market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, rising adoption of population-based genetic screening, expansion of AI-driven variant interpretation, growing integration of genomics in clinical decision making, increasing focus on preventive cardiovascular healthcare. Major trends in the forecast period include increasing adoption of predictive genetic risk assessment, rising use of multigene panel testing, growing integration of bioinformatics and AI analytics, expansion of pharmacogenomic testing applications, enhanced focus on personalized cardiovascular care.

The rising prevalence of cardiovascular diseases is projected to support the growth of the cardiovascular genetic testing market in the coming years. Cardiovascular diseases (CVDs) include a range of disorders affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases is increasing largely due to sedentary lifestyles linked to urbanization, which contribute to obesity, high blood pressure, and metabolic conditions. The growing incidence of cardiovascular diseases increases demand for cardiovascular genetic testing, as early identification of genetic risks enables personalized prevention strategies and targeted treatments to reduce the risk of severe heart complications. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the cardiovascular genetic testing market.

Leading companies operating in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and customization based on patient-specific conditions, reducing unnecessary testing and associated costs. A clinician-ordered test is a diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient's health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine, launched a genetic test evaluating inherited risk for eight cardiovascular conditions. The clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to conditions such as atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH's All of Us Research Program. Publicly available polygenic risk scores were integrated using PRSmix, an elastic-net modeling approach combining multiple component scores into a single comprehensive risk score per disease. High-resolution genetic data is captured through a blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets results and generates patient-friendly reports.

In February 2025, Tempus AI Inc., a US-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. This acquisition strengthens Tempus AI's strategy of combining diagnostics and data-driven insights to fuel innovation, enhancing its ability to deliver advanced solutions to healthcare providers, patients, and life sciences organizations. Ambry Genetics Corporation is a US-based company focused on cardiovascular genetic testing services.

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiovascular genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiovascular genetic testing market includes revenues earned by entities through genetic testing services, genetic screening services, molecular diagnostic services, genomic sequencing services, variant interpretation services, bioinformatics analysis services, genetic counseling services, and personalized risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiovascular Genetic Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cardiovascular genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiovascular genetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiovascular genetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
  • 2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
  • 3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
  • 4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
  • 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
  • Subsegments:
  • 1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
  • 2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
  • 3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
  • 4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
  • 5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
  • 6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
  • Companies Mentioned: Labcorp Holdings Inc.; Quest Diagnostics Inc.; ICON plc; Illumina Inc.; Apollo Hospitals; OPKO Health Inc.; Revvity Inc.; ARUP Laboratories Inc.; Mayo Clinic Laboratories; Fulgent Genetics Inc.; MedGenome Inc.; Genome Medical; PreventionGenetics; Eurofins Genomics LLC; Blueprint Genetics Inc.; MapmyGenome; GENinCode; Allelica Srl; Rocket Pharma Inc.; and Health in Code SL.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cardiovascular Genetic Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cardiovascular Genetic Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cardiovascular Genetic Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cardiovascular Genetic Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Artificial Intelligence & Autonomous Intelligence
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Predictive Genetic Risk Assessment
    • 4.2.2 Rising Use Of Multigene Panel Testing
    • 4.2.3 Growing Integration Of Bioinformatics And AI Analytics
    • 4.2.4 Expansion Of Pharmacogenomic Testing Applications
    • 4.2.5 Enhanced Focus On Personalized Cardiovascular Care

5. Cardiovascular Genetic Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutions
  • 5.4 Genetic Counseling Centers
  • 5.5 Pharmaceutical Companies

6. Cardiovascular Genetic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cardiovascular Genetic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cardiovascular Genetic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cardiovascular Genetic Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cardiovascular Genetic Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cardiovascular Genetic Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cardiovascular Genetic Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cardiovascular Genetic Testing Market Segmentation

  • 9.1. Global Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Predictive Testing, Carrier Testing, Prenatal And Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Other Testing Types
  • 9.2. Global Cardiovascular Genetic Testing Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, Other Diseases
  • 9.3. Global Cardiovascular Genetic Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cytogenetic Testing, Biochemical Testing, Molecular Testing
  • 9.4. Global Cardiovascular Genetic Testing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Applications
  • 9.5. Global Cardiovascular Genetic Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Diagnostic Laboratories, Research Institutions, Genetic Counseling Centers, Pharmaceutical Companies, Direct-To-Consumer Testing
  • 9.6. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Predictive Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Presymptomatic Risk Assessment, Familial Variant Screening, Polygenic Risk Evaluation, Late Onset Disease Prediction, Susceptibility Gene Testing
  • 9.7. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Carrier Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Autosomal Recessive Carrier Screening, Linked Carrier Screening, Expanded Carrier Screening Panels, Single Gene Carrier Screening, Family History Based Carrier Testing
  • 9.8. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Prenatal And Newborn Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Non Invasive Prenatal Genetic Testing, Invasive Prenatal Diagnostic Testing, Newborn Metabolic Screening, Congenital Heart Disease Genetic Screening, Neonatal Gene Panel Testing
  • 9.9. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Diagnostic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Single Gene Diagnostic Testing, Multigene Panel Diagnostic Testing, Whole Exome Diagnostic Testing, Whole Genome Diagnostic Testing, Variant Confirmation Testing
  • 9.10. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Pharmacogenomic Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Drug Response Gene Testing, Adverse Drug Reaction Risk Testing, Dose Optimization Genetic Testing, Anticoagulant Response Testing, Cardiovascular Drug Metabolism Testing
  • 9.11. Global Cardiovascular Genetic Testing Market, Sub-Segmentation Of Other Testing Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cascade Family Testing, Population Based Genetic Screening, Research Use Genetic Testing, Confirmatory Follow Up Testing, Clinical Trial Genetic Testing

10. Cardiovascular Genetic Testing Market Regional And Country Analysis

  • 10.1. Global Cardiovascular Genetic Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cardiovascular Genetic Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cardiovascular Genetic Testing Market

  • 11.1. Asia-Pacific Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cardiovascular Genetic Testing Market

  • 12.1. China Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cardiovascular Genetic Testing Market

  • 13.1. India Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cardiovascular Genetic Testing Market

  • 14.1. Japan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cardiovascular Genetic Testing Market

  • 15.1. Australia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cardiovascular Genetic Testing Market

  • 16.1. Indonesia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cardiovascular Genetic Testing Market

  • 17.1. South Korea Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cardiovascular Genetic Testing Market

  • 18.1. Taiwan Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cardiovascular Genetic Testing Market

  • 19.1. South East Asia Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cardiovascular Genetic Testing Market

  • 20.1. Western Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cardiovascular Genetic Testing Market

  • 21.1. UK Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cardiovascular Genetic Testing Market

  • 22.1. Germany Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cardiovascular Genetic Testing Market

  • 23.1. France Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cardiovascular Genetic Testing Market

  • 24.1. Italy Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cardiovascular Genetic Testing Market

  • 25.1. Spain Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cardiovascular Genetic Testing Market

  • 26.1. Eastern Europe Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cardiovascular Genetic Testing Market

  • 27.1. Russia Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cardiovascular Genetic Testing Market

  • 28.1. North America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cardiovascular Genetic Testing Market

  • 29.1. USA Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cardiovascular Genetic Testing Market

  • 30.1. Canada Cardiovascular Genetic Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cardiovascular Genetic Testing Market

  • 31.1. South America Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cardiovascular Genetic Testing Market

  • 32.1. Brazil Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cardiovascular Genetic Testing Market

  • 33.1. Middle East Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cardiovascular Genetic Testing Market

  • 34.1. Africa Cardiovascular Genetic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cardiovascular Genetic Testing Market, Segmentation By Testing Type, Segmentation By Disease, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cardiovascular Genetic Testing Market Regulatory and Investment Landscape

36. Cardiovascular Genetic Testing Market Competitive Landscape And Company Profiles

  • 36.1. Cardiovascular Genetic Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cardiovascular Genetic Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cardiovascular Genetic Testing Market Company Profiles
    • 36.3.1. Labcorp Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Quest Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. ICON plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Apollo Hospitals Overview, Products and Services, Strategy and Financial Analysis

37. Cardiovascular Genetic Testing Market Other Major And Innovative Companies

  • OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., Health in Code SL

38. Global Cardiovascular Genetic Testing Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Cardiovascular Genetic Testing Market

41. Cardiovascular Genetic Testing Market High Potential Countries, Segments and Strategies

  • 41.1 Cardiovascular Genetic Testing Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Cardiovascular Genetic Testing Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Cardiovascular Genetic Testing Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer